Adele Gulfo

Chief of Commercial Development, Roivant Sciences

Adele Gulfo

Adele Gulfo serves as Roivant Sciences’ Chief of Commercial Development. Before this position, she was Mylan’s EVP and Chief Strategy Officer. As a member of the Executive Leadership Team, she focused on Mylan’s key growth drivers, including the company’s expansion in Latin America and the development and growth of its global Specialty franchise.

Previously, Gulfo served as president and general manager of Pfizer’s U.S. Primary Care business unit, which included the Managed Markets (corporate and governmental customers) organization for all of Pfizer’s Biopharmaceutical business units.  Under her leadership, Pfizer’s U.S. Primary Care business generated more than $13 billion in revenue.  Earlier in her career at Pfizer, Gulfo was instrumental in the launch and commercial success of LIPITOR, which became the world’s best-selling medicine. She was also recognized for developing marketing and medical education campaigns that helped to establish the significance of lowering LDL cholesterol in preventing and managing heart disease.

Immediately prior to joining Mylan, Gulfo served as regional president of Latin America in Pfizer’s Emerging Markets business unit. In this capacity, she led a team of more than 4,000 colleagues operating across approximately two dozen countries. In 2012, under her leadership, the Latin American business achieved more than $3 billion in revenue, making it the largest revenue generator within the unit.

Prior to joining Pfizer, Gulfo led AstraZeneca’s multi-billion dollar cardiovascular business. Among her achievements, she grew Toprol-XL® sales from $200 million to $2 billion and launched cholesterol-lowering medicine Crestor® with a significantly differentiated life-cycle development program, growing it to a more than $2 billion product in 2009. She then became vice president of Business Development, Innovation and Design for Launch at Astra-Zeneca Pharmaceuticals.

Trained as a scientist with experience in both operational and strategic roles, Gulfo has been awarded five U.S. patents for innovative packaging designed to help patients adhere to their medicines. She serves as an innovation advisor to PARTNERS Healthcare, the $10 billion Boston-based healthcare system, and Cleveland Clinic’s Innovation Center. She also serves on the board of directors for Volunteers of America (VOA) – Greater New York, and the Committee of 200 (C200), the world’s premier women’s business leadership organization.